UT Health San Antonio Becomes First Civilian Center in South Texas to Launch FDA-Approved Radiotherapy Treatment for Advanced Prostate Cancer
October 07, 2023
October 07, 2023
SAN ANTONIO, Texas, Oct. 7 -- The University of Texas Health Science Center at San Antonio issued the following news release:
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer.
Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers ra . . .
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer.
Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers ra . . .